Scientists at Kindred Companion Sciences have successfully used CRISPR gene editing to create the first hypoallergenic beagles, opening a potential path for millions of people with pet allergies to own dogs without the physical toll that's long kept them from doing so. The two healthy female pups—Bailey and her twin Alfie—were born to a beagle surrogate about two years ago and represent a breakthrough that could reshape who gets to experience pet ownership.
For many Americans, dog allergies aren't a minor inconvenience. They're a barrier to companionship. Matt Walker, a geneticist at Kindred Companion Sciences, spent his childhood unable to pet dogs without sneezing. Even breeds marketed as hypoallergenic, like his family's goldendoodle, triggered itchy eyes and painful rashes. Now, after a little over one year with Bailey, he can feed her peanut butter from a spoon while she lies on his lap and play fetch in Central Park. "It feels just amazing to get to have a dog," he said.
The research, published Wednesday in the CRISPR Journal, involved editing the genetic code inside dog skin cells to switch off the main gene responsible for producing allergy-causing proteins. Scientists transferred the edited genetic code into eggs that were implanted in a beagle surrogate. When Bailey and Alfie were born, tests of their saliva and fur showed no signs of the allergy-causing protein. In a direct test, Walker's skin reacted to samples from a standard poodle and goldendoodle but showed no reaction to extracts from the gene-edited beagles' saliva and dander.
How the Science Works
The technique targets a fundamental problem with existing "hypoallergenic" breeds. Dogs like poodles shed less fur, but they still produce allergy-causing proteins in their saliva, hair, and dander. Walker explained that all dogs carry the same allergy-causing gene that was edited out of Bailey and Alfie. The edit itself is rare but does occur naturally in some dogs, making it unlikely to have negative health effects. Still, Walker emphasized the importance of monitoring the dogs at routine vet visits to ensure they stay healthy.
Previous attempts to create hypoallergenic pets mostly relied on cloning, which produced sicker animals that were too genetically similar. About two years ago, researchers used CRISPR to reduce levels of an allergy-causing protein in a cat named Alsik, but it remains unclear whether that technique is safe to test more broadly on other cats.
The Equity Question
Bioethicist Arthur Caplan of New York University's Grossman School of Medicine acknowledged both the promise and the pitfall. "It opens the door to a lot more people being able to own pets," Caplan said. "On the negative side, it may discourage people from trying to use strays and unwanted animals that are not engineered to be allergy-free." The concern reflects a real tension: a technology that expands access for some could devalue shelter animals and widen the gap between those who can afford engineered pets and those who adopt from existing populations.
Kindred Companion Sciences plans to test the technique on other dog breeds and service animals. But Dr. Jeff SoRelle, a pathologist at University of Texas Southwestern Medical Center, urged caution. "We don't exactly know just how effective or broadly useful this could be for stopping dog allergy in humans," SoRelle said. Future research should test gene-edited hypoallergenic dogs on more people with pet allergies to confirm the technique works across a broader population.
Bailey lives with Walker in New York, while Alfie lives in Florida with another Kindred scientist. Both have become family members to their respective owners—a small but meaningful outcome of a technology that could eventually allow millions of people to experience what Walker described as the simple joy of having a dog.
Why This Matters:
Pet allergies affect roughly 10 percent of the population in developed countries, creating a real form of exclusion from pet ownership. This breakthrough could democratize access to dog companionship for people who've been locked out by biology. However, the emergence of expensive, engineered pets raises critical questions about equity and resource allocation. Will gene-edited hypoallergenic dogs become luxury items available only to the wealthy, while shelter animals languish? Will this technology incentivize breeding designer dogs over adoption? The regulatory and market structures that develop around this innovation will determine whether it expands opportunity broadly or narrows it further. As this technology moves from laboratory to commerce, decisions about pricing, accessibility, and how it affects adoption rates will shape whether gene editing becomes a tool for inclusion or another marker of inequality.